WO2020005877A1 - Heteroaryl compounds for treating huntington's disease - Google Patents

Heteroaryl compounds for treating huntington's disease Download PDF

Info

Publication number
WO2020005877A1
WO2020005877A1 PCT/US2019/038895 US2019038895W WO2020005877A1 WO 2020005877 A1 WO2020005877 A1 WO 2020005877A1 US 2019038895 W US2019038895 W US 2019038895W WO 2020005877 A1 WO2020005877 A1 WO 2020005877A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
thiazolo
fluoro
pyridin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/038895
Other languages
English (en)
French (fr)
Inventor
Nanjing Zhang
Suresh Babu
Scott J. Barraza
Anuradha Bhattacharyya
Guangming Chen
Gary Mitchell Karp
Andrew J. Kassick
Anthony R. Mazzotti
Young-Choon Moon
Jana Narasimhan
Nadiya Sydorenko
Anthony Turpoff
Matthew G. WOLL
Wuming YAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112020026534-9A priority Critical patent/BR112020026534A2/pt
Priority to EP19736947.3A priority patent/EP3814345B8/en
Priority to AU2019294482A priority patent/AU2019294482B2/en
Priority to KR1020207036998A priority patent/KR20210038845A/ko
Priority to US17/254,828 priority patent/US12139499B2/en
Priority to JP2020572894A priority patent/JP7515415B2/ja
Priority to CN201980050967.1A priority patent/CN112805280B/zh
Priority to NZ771342A priority patent/NZ771342B2/en
Priority to EA202092899A priority patent/EA202092899A1/ru
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Priority to MX2020014315A priority patent/MX2020014315A/es
Priority to SG11202012869SA priority patent/SG11202012869SA/en
Priority to CA3104516A priority patent/CA3104516A1/en
Publication of WO2020005877A1 publication Critical patent/WO2020005877A1/en
Priority to IL279714A priority patent/IL279714A/en
Anticipated expiration legal-status Critical
Priority to AU2022209304A priority patent/AU2022209304A1/en
Priority to JP2024072881A priority patent/JP2024105367A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • An aspect of the present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof useful for treating or ameliorating Huntington’s disease.
  • another aspect of the present description relates to substituted benzothiazole compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington’s disease.
  • Huntington’s disease is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent.
  • the disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the“mutant” huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a“CAG repeat” sequence.
  • Htt huntingtin
  • polyQ poly-glutamine
  • An aspect of the present description includes compounds comprising, a compound of Formula (I) or Formula (II):
  • R 1 , R 2 , X, W 1 , W 2 , and W 3 are as defined herein.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising,
  • An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof in combination with an effective amount of the one or more agents.
  • An aspect of the present description relates to compounds comprising, a compound of Formula (I) or Formula (II):
  • W1, W2 and W3 are independently C-Ra or N;
  • Ra is, in each instance, independently selected from hydrogen, cyano, halogen, hydroxy, C1-6alkyl, halo-C 1-6 alkyl, C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy-carbonyl, amino, C 1-6 alkyl-amino, (C 1-6 alkyl) 2 -amino, amino-C 1-6 alkyl, and hydroxy-C1-6alkyl;
  • X is selected from N-Rb, O, or a bond
  • R b is selected from hydrogen and C 1-6 alkyl
  • R1 is selected from C3-10cycloalkyl and heterocyclyl
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic
  • each instance of C3-10cycloalkyl and heterocyclyl is optionally substituted with one, two three, or four R 3 substituents and optionally, with one additional R 4 substituent, or, wherein, alternatively, each instance of C 3-10 cycloalkyl and heterocyclyl is optionally substituted with one, two, three, four, or five R3 substituents;
  • R3 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl,
  • halo-C 1-6 alkyl C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C1-6alkoxy-carbonyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, and hydroxy-C1-6alkyl;
  • R 4 is selected from C 3-10 cycloalkyl, phenyl, heterocyclyl, and heteroaryl;
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic
  • R2 is selected from phenyl and heteroaryl
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
  • each instance of phenyl and heteroaryl is optionally substituted with one, two or three R5 substituents and optionally, with one additional R6 substituent, or,
  • each instance of phenyl and heteroaryl is optionally substituted with one, two, three or four R5 substituents;
  • R5 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl,
  • halo-C 1-6 alkyl C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C1-6alkoxy-carbonyl, C1-6alkoxy-carbonyl-C1-6alkyl, carboxyl, C1-6alkyl-carboxyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, amino-carbonyl, and
  • R 6 is selected from C 3-10 cycloalkyl, phenyl, phenyl-C 1-6 alkoxy, phenyl-oxy, heterocyclyl, and heteroaryl;
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, and wherein, each instance of C3-10cycloalkyl, phenyl, heterocyclyl, and heteroaryl is optionally
  • R 7 is, in each instance, independently selected from cyano, halogen, hydroxy, C 1-6 alkyl,
  • halo-C 1-6 alkyl C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C1-6alkoxy-carbonyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, and hydroxy-C1-6alkyl;
  • a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
  • Another aspect of the present description includes a compound of Formula (I) or Formula (II):
  • W 1 , W 2 and W 3 are independently C-R a or N;
  • R a is, in each instance, independently selected from hydrogen, cyano, halogen, hydroxy, C 1-6 alkyl, halo-C1-6alkyl, C1-6alkyl-carbonyl, C1-6alkoxy, halo-C1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkoxy-carbonyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, and hydroxy-C 1-6 alkyl;
  • X is selected from N-R b , O, or a bond
  • Rb is selected from hydrogen and C1-6alkyl
  • R 1 is selected from C 3-10 cycloalkyl and heterocyclyl
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic
  • each instance of C 3-10 cycloalkyl and heterocyclyl is optionally substituted with one, two three, or four R3 substituents and optionally, with one additional R4 substituent, or, wherein, alternatively, each instance of C3-10cycloalkyl and heterocyclyl is optionally substituted with one, two, three, four, or five R 3 substituents;
  • R3 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl,
  • halo-C1-6alkyl C1-6alkyl-carbonyl, C1-6alkoxy, halo-C1-6alkoxy, C1-6alkoxy-C1-6alkyl, C 1-6 alkoxy-carbonyl, amino, C 1-6 alkyl-amino, (C 1-6 alkyl) 2 -amino, amino-C 1-6 alkyl, and hydroxy-C 1-6 alkyl;
  • R4 is selected from C3-10cycloalkyl, phenyl, heterocyclyl, and heteroaryl; wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, and wherein, each instance of C 3-10 cycloalkyl, phenyl, heterocyclyl, and heteroaryl is optionally
  • R2 is selected from phenyl and heteroaryl
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
  • each instance of phenyl and heteroaryl is optionally substituted with one, two or three R5 substituents and optionally, with one additional R6 substituent, or,
  • each instance of phenyl and heteroaryl is optionally substituted with one, two, three or four R5 substituents;
  • R5 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl,
  • halo-C 1-6 alkyl C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy-carbonyl, C 1-6 alkoxy-carbonyl-C 1-6 alkyl, carboxyl, C 1-6 alkyl-carboxyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, amino-carbonyl, and
  • R 6 is selected from C 3-10 cycloalkyl, phenyl, phenyl-C 1-6 alkoxy, phenyl-oxy, heterocyclyl, and heteroaryl;
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, and wherein, each instance of C 3-10 cycloalkyl, phenyl, heterocyclyl, and heteroaryl is optionally
  • R7 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl,
  • halo-C 1-6 alkyl C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C1-6alkoxy-carbonyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, and hydroxy-C1-6alkyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W 1 , W 2 and W 3 are C-Ra.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W1 is N.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein W 1 is N, and W 2 and W 3 are C-R a .
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W2 is N.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein W2 is N, and W 1 and W 3 are C-R a .
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W3 is N.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein W3 is N, and W 1 and W 2 are C-R a .
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W1 and W2 are N.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein W 1 and W 2 are N and W 3 is C-R a .
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W1 and W3 are N.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein W 1 and W 3 are N and W2 is C-Ra.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W2 and W3 are N.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein W2 and W3 are N and W2 is C-Ra.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein W 1 , W 2 and W 3 are N.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein Ra is, in each instance, independently selected from hydrogen, cyano, halogen, hydroxy, C1-6alkyl,
  • halo-C 1-6 alkyl C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C1-6alkoxy-carbonyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, and hydroxy-C1-6alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R a is, in each instance, independently selected from hydrogen, cyano, halogen, hydroxy, and C1-6alkoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein Ra is, in each instance, hydrogen.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R a is, in each instance, cyano.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein Ra is, in each instance, halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein Ra is, in each instance, halogen selected from chloro and fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R a is, in each instance, hydroxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein Ra is, in each instance, C 1-6 alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R a is, in each instance, methoxy.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein X is selected from N-R b , O, or a bond.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein X is N-Rb. Another aspect includes a compound of Formula (I) or Formula (II), wherein X is O. Another aspect includes a compound of Formula (I) or Formula (II), wherein X is a bond. One aspect includes a compound of Formula (I) or Formula (II), wherein Rb is selected from hydrogen and C1-6alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R b is hydrogen.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein Rb is C1-6alkyl selected from methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R b is C1-6alkyl selected from methyl and ethyl.
  • R b is C1-6alkyl selected from methyl and ethyl.
  • R1 is selected from C3-10cycloalkyl and heterocyclyl,
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, and
  • each instance of C 3-10 cycloalkyl and heterocyclyl is optionally substituted with one, two three, or four R 3 substituents and optionally, with one additional R 4 substituent, or, wherein, alternatively, each instance of C3-10cycloalkyl and heterocyclyl is optionally substituted with one, two, three, four, or five R3 substituents.
  • R 1 is C3-10cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl, optionally substituted with one, two three, or four R 3 substituents and optionally, with one additional R 4 substituent, or, alternatively, optionally substituted with one, two, three, four, or five R3 substituents.
  • R 1 is C3-10cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl, optionally substituted with one, two three, or four R 3 substituents and optionally, with one additional R 4 substituent, or, alternatively, optional
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1 is C 3-10 cycloalkyl selected from cylcobutyl and cyclohexyl, optionally substituted with one, two three, or four R 3 substituents and optionally, with one additional R 4 substituent, or, alternatively, optionally substituted with one, two, three, four, or five R3 substituents.
  • R1 is C 3-10 cycloalkyl selected from cylcobutyl and cyclohexyl, optionally substituted with one, two three, or four R 3 substituents and optionally, with one additional R 4 substituent, or, alternatively, optionally substituted with one, two, three, four, or five R3 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1 is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1H-azepinyl, 2,3,6,7-tetrahydro-1H-azepinyl, azepanyl, 1,4-diazepanyl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1 is heterocyclyl selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2,3,6,7-tetrahydro- 1H-azepinyl, azepanyl, 1,4-diazepanyl, 1,2,3,6-tetrahydropyridinyl, octahydroindolizinyl, octahydro-1H-pyrrolo[3,2-c]pyridinyl, (3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridinyl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1 is heterocyclyl selected from azetidin-2-yl, azetidin-3-yl, tetrahydrofuran-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, 1H-azepin-2-yl, 1H-azepin-3-yl, 1H-azepin-4-yl, 2,3,6,7-tetrahydro-1H-azepin-4- yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, 1,4-diazepan-1-yl, 1,4-diazepan-2-yl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R1 is heterocyclyl selected from azetidin-3-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2,3,6,7-tetrahydro-1H-azepin-4-yl, azepan-4-yl, 1,4-diazepan-1-yl, 1,2,3,6-tetrahydropyridin-4-yl, octahydroindolizin-7-yl, octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, (3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, 1-azabicyclo[2.2.2]oct-4-yl,
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl, halo-C1-6alkyl, C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy-carbonyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, and hydroxy-C1-6alkyl.
  • R3 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl, halo-C1-6alkyl, C 1-6 alkyl-carbonyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxy-carbonyl, amino, C1-6alkyl
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, independently selected from halogen, hydroxy, C1-6alkyl, halo-C1-6alkyl, amino, C 1-6 alkyl-amino, (C 1-6 alkyl) 2 -amino, and hydroxy-C 1-6 alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is, in each instance, fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, hydroxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is, in each instance, C1-6alkyl selected from methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, C 1-6 alkyl selected from methyl and ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, halo-C1-6alkyl, wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more halogens selected from bromo, chloro, fluoro, and iodo where allowed by available valences.
  • R3 is, in each instance, halo-C1-6alkyl, wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more halogens selected from bromo, chloro, fluoro, and iodo where allowed by available valences.
  • Another aspect includes a compound of Formula (I), wherein R3 is, in each instance, halo- C1-6alkyl selected from fluoroethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 3 is, in each instance, amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, C 1-6 alkyl-amino wherein C 1-6 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I), wherein R3 is, in each instance, methylamino.
  • Another aspect includes a compound of Formula (I), wherein R 3 is, in each instance, (C1-6alkyl)2-amino wherein C1-6alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I), wherein R 3 is, in each instance, dimethylamino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R3 is, in each instance, hydroxy-C1-6alkyl, wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more hydroxy groups where allowed by available valences.
  • Another aspect includes a compound of Formula (I), wherein R3 is, in each instance, hydroxy-C 1-6 alkyl selected from hydroxymethyl and hydroxyethyl.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is selected from C3-10cycloalkyl, phenyl, heterocyclyl, and heteroaryl;
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S,
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, and
  • each instance of C3-10cycloalkyl, phenyl, heterocyclyl, and heteroaryl is optionally substituted with one, two or three R7 substituents.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is
  • C 3-10 cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl, optionally substituted with one, two or three R7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 4 is cyclopropyl, optionally substituted with one, two or three R7 substituents.
  • One aspect includes a compound of Formula (I) or Formula (II), wherein R2 is selected from phenyl and heteroaryl,
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S,
  • each instance of phenyl and heteroaryl is optionally substituted with one, two or three R 5 substituents and optionally, with one additional R 6 substituent, or,
  • each instance of phenyl and heteroaryl is optionally substituted with one, two, three or four R5 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is phenyl, optionally substituted with one, two or three R5 substituents and optionally, with one additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R5 substituents.
  • R 2 is heteroaryl selected from furanyl, 1H-pyrazolyl, 1H-imidazolyl, 1H-1,2,3-triazolyl, 4H-1,2,4- triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl,
  • pyrrolo[1,2-b]pyridazinyl pyrazolo[1,5-a]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, 2H- pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[1,5- a]pyrimidinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,5-a]pyridinyl,
  • imidazo[2,1-b][1,3]thiazolyl imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridnyl, [1,2,4]triazolo[1,5-b]pyridazinyl, and quinolinyl, optionally substituted with one, two or three R 5 substituents and optionally, with one additional R 6 substituent, or, alternatively, optionally substituted with one, two, three or four R 5 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heteroaryl selected from 1H-indazolyl, 2H-indazolyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, furo[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, 1H-pyrazolo[4,3-b]pyridinyl, 2H- pyrazolo[4,3-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl,
  • imidazo[2,1-b][1,3]thiazolyl imidazo[2,1-b][1,3,4]thiadiazolyl, [1,2,4]triazolo[1,5-a]pyridnyl, and [1,2,4]triazolo[1,5-b]pyridazinyl, optionally substituted with one, two or three R5 substituents and optionally, with one additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R 5 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 2 is heteroaryl selected from furan-2-yl, furan-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R2 is heteroaryl selected from 1H-indazol-5-yl, 2H-indazol-5-yl, 1H-benzimidazol-6-yl,
  • 1,3-benzoxazol-6-yl furo[2,3-b]pyridine-6-yl, pyrrolo[1,2-a]pyrazin-7-yl, 1H-pyrazolo[4,3- b]pyridin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, pyrazolo[1,5-a]pyrimidin-5-yl,
  • R5 is, in each instance, independently selected from cyano, halogen, hydroxy, C 1-6 alkyl, halo-C 1-6 alkyl, C1-6alkyl-carbonyl, C1-6alkoxy, halo-C1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkoxy-carbonyl, C1-6alkoxy-carbonyl-C1-6alkyl, carboxyl, C1-6alkyl-carboxyl, amino, C1-6alkyl-amino, (C1-6alkyl)2-amino, amino-C1-6alkyl, amino-carbonyl, and hydroxy-C1-6alkyl.
  • R 5 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl, halo-C1-6alkyl, C1-6alkoxyC1-6alkoxy-carbonyl-C1-6alkyl, carboxyl, C1-6alkyl-carboxyl, amino, C1-6alkyl-amino, (C 1-6 alkyl) 2 -amino, amino-C 1-6 alkyl, and amino-carbonyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is, in each instance, cyano.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, fluoro.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is, in each instance, hydroxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, C 1-6 alkyl selected from methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is, in each instance, C1-6alkyl selected from methyl and ethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, halo-C 1-6 alkyl, wherein C 1-6 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more halogens selected from bromo, chloro, fluoro, and iodo where allowed by available valences.
  • R5 is, in each instance, halo-C 1-6 alkyl, wherein C 1-6 alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl partially or completely substituted with one or more halogens selected from bromo, chloro, fluoro, and iodo where allowed by available valences.
  • Another aspect includes a compound of Formula (I), wherein R 5 is, in each instance, halo- C1-6alkyl selected from trifluoromethyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, C 1-6 alkoxy selected from methoxy, ethoxy, propoxy, isopropoxy, and tert-butoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R a is, in each instance, methoxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, C 1-6 alkoxy-carbonyl-C 1-6 alkyl, wherein C 1-6 alkoxy is selected from methoxy, ethoxy, propoxy, isopropoxy, and tert-butoxy, and wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is, in each instance, -CH2CO2CH3.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, carboxyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is, in each instance, C1-6alkyl-carboxyl, wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 5 is, in each instance, -CH2CO2H.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, amino.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R5 is, in each instance, C1-6alkyl-amino wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I), wherein R 5 is, in each instance, methylamino.
  • Another aspect includes a compound of Formula (I), wherein R5 is, in each instance, (C 1-6 alkyl) 2 -amino wherein C 1-6 alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I), wherein R5 is, in each instance, dimethylamino.
  • Another aspect includes a compound of Formula (I), wherein R5 is, in each instance, amino-C1-6alkyl wherein C1-6alkyl is independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
  • Another aspect includes a compound of Formula (I), wherein R 5 is, in each instance, methanamine.
  • Another aspect includes a compound of Formula (I), wherein R5 is, in each instance, amino-carbonyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R6 is selected from C3-10cycloalkyl, phenyl, phenyl-C1-6alkoxy, phenyl-oxy, heterocyclyl, and heteroaryl;
  • heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic
  • heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, or S, and wherein, each instance of C3-10cycloalkyl, phenyl, heterocyclyl, and heteroaryl is optionally substituted with one, two or three R 7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R6 is C3-10cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl, optionally substituted with one, two or three R 7 substituents.
  • R6 is C3-10cycloalkyl selected from cyclopropyl, cylcobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexanyl, and adamantyl, optionally substituted with one, two or three R 7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R6 is cyclopropyl, optionally substituted with one, two or three R 7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 6 is phenyl- C1-6alkoxy, wherein C1-6alkoxy is selected from methoxy, ethoxy, propoxy, isopropoxy, and tert- butoxy, and wherein C1-6alkyl is selected from methyl, ethyl, propyl, isopropyl, and tert-butyl, and wherein, phenyl is optionally substituted with one, two or three R 7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R6 is benzyloxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 6 is phenyl- oxy, wherein, phenyl is optionally substituted with one, two or three R7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R6 is benzyloxy.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 6 is heteroaryl selected from furanyl, 1H-pyrazolyl, 1H-imidazolyl, 1H-1,2,3-triazolyl, 4H-1,2,4- triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl, optionally substituted with one, two or three R 7 substituents.
  • R6 is heteroaryl selected from 1H-pyrazolyl and 1H-imidazolyl, optionally substituted with one, two or three R 7 substituents.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R6 is heteroaryl selected from furan-2-yl, furan-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 6 is heteroaryl selected from 1H-pyrazol-4-yl and 1H-imidazol-1-yl, optionally substituted with one, two or three R7 substituents.
  • R 7 is, in each instance, independently selected from cyano, halogen, hydroxy, C1-6alkyl, halo-C1-6alkyl, C1-6alkyl-carbonyl, C1-6alkoxy, halo-C1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkoxy-carbonyl, amino, C 1-6 alkyl-amino, (C 1-6 alkyl) 2 -amino, amino-C 1-6 alkyl, and hydroxy-C 1-6 alkyl.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 7 is, in each instance, halogen, hydroxy, C1-6alkyl, halo-C1-6alkyl, C1-6alkyl-carbonyl, C1-6alkoxy,
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R7 is, in each instance, halogen selected from bromo, chloro, fluoro, and iodo.
  • Another aspect includes a compound of Formula (I) or Formula (II), wherein R 7 is, in each instance, fluoro.
  • One aspect of the compound of Formula (I) includes a compound selected from Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), or Formula (Ih):
  • Another aspect of the compound of Formula (I) includes a compound selected from Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), or Formula (Ig):
  • One aspect of the compound of Formula (II) includes a compound selected from Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), Formula (IIf), Formula (IIg) or Formula (IIh):
  • Another aspect of the compound of Formula (II) includes a compound selected from Formula (IIa) or Formula (IIb):
  • One aspect of the compound of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig) or Formula (Ih) includes a compound selected from Formula (Ia1), Formula (Ib1), Formula (Ic1), Formula (Id1), Formula (Ie1), Formula (If1), Formula (Ig1), or Formula (Ih1):
  • Another aspect of the compound of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If) or Formula (Ig) includes a compound selected from Formula (Ia1), Formula (Ib1), Formula (Ic1), Formula (Id1), Formula (Ie1), Formula (If1), or Formula (Ig1):
  • One aspect of the compound of Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), Formula (IIf), Formula (IIg) or Formula (IIh) includes a compound selected from Formula (IIa1), Formula (IIb1), Formula (Ic1), Formula (IId1), Formula (IIe1), Formula (IIf1), Formula (IIg1) or Formula (IIh1):
  • Another aspect of the compound of Formula (IIa) or Formula (IIb) includes a compound selected from Formula (IIa1) or Formula (IIb1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (Ia1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (Ib1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (Ic1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (Id1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (Ie1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (If1):
  • Another aspect of the compound of Formula (I) includes the compound of Formula (Ig1):
  • Another aspect of the compound of Formula (II) includes the compound of Formula (IIa1):
  • Another aspect of the compound of Formula (II) includes the compound of Formula (IIb1):
  • An aspect of the compound of Formula (I) or Formula (II) or a form thereof includes a compound selected from the group consisting of:
  • a form of the compound is selected from the group consisting of a salt, hydrate, solvate, racemate, enantiomer, diastereomer, stereoisomer, and tautomer form thereof.
  • An aspect the compound of Formula (I) or Formula (II) or a form thereof includes a compound selected from the group consisting of:
  • Another aspect of the compound of Formula (I) or Formula (II) or a form thereof is a compound salt selected from the group consisting of:
  • An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a method for use of a compound of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form or composition thereof.
  • Another aspect of the present description includes a method for use of a compound salt of Formula (I) or Formula (II) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.
  • An aspect of the present description includes a use for a compound of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • Another aspect of the present description includes a use for a compound salt of Formula (I) or Formula (II) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of the one or more agents.
  • C1-6alkyl generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration, including, but not limited to, methyl, ethyl, n-propyl (also referred to as propyl or propanyl), isopropyl, n-butyl (also referred to as butyl or butanyl), isobutyl, sec-butyl, tert-butyl, n-pentyl (also referred to as pentyl or pentanyl), n-hexyl (also referred to as hexyl or hexanyl), and the like.
  • C 1-6 alkyl includes, but is not limited to, C 1-4 alkyl, C 1-2 alkyl and the like.
  • a C 1-6 alkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C2-8alkenyl generally refers to partially unsaturated
  • hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, but not limited to, ethenyl (also referred to as vinyl), allyl, propenyl and the like.
  • C2-8alkenyl includes, but is not limited to, C 2-6 alkenyl, C 2-4 alkenyl and the like.
  • a C 2-8 alkenyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C 2-8 alkynyl generally refers to partially unsaturated
  • hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, but not limited to, ethynyl, propynyl, butynyl and the like.
  • C2-8alkynyl includes, but is not limited to, C 2-6 alkynyl, C 2-4 alkynyl and the like.
  • a C 2-8 alkynyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C1-6alkoxy generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration of the formula: -O-C168alkyl, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy and the like.
  • C 1-6 alkoxy includes, but is not limited to, C 1-4 alkoxy, C 1-2 alkoxy and the like.
  • C 1-6 alkoxy radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • C3-10cycloalkyl generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthalenyl and the like.
  • C3-10cycloalkyl includes, but is not limited to, C3-8cycloalkyl, C5-8cycloalkyl, and the like.
  • a C3-10cycloalkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • aryl generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like.
  • An aryl radical is optionally substituted with substituent species as described herein where allowed by available valences.
  • heteroaryl generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more
  • heteroatoms such as an O, S or N atom, including, but not limited to, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoimidazolyl, 1,3-benzothiazolyl,
  • 1,3-benzoxazolyl purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, 1,3-diazinyl, 1,2-diazinyl, 1,2-diazolyl, 1,4-diazanaphthalenyl, acridinyl, furo[3,2-b]pyridinyl,
  • a heteroaryl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.
  • heteroaryl radical may differ, such as in non- limiting examples where furanyl may also be referred to as furyl, thienyl may also be referred to as thiophenyl, pyridinyl may also be referred to as pyridyl, benzothienyl may also be referred to as benzothiophenyl and 1,3-benzoxazolyl may also be referred to as 1,3-benzooxazolyl.
  • the term for a heteroaryl radical may also include other regioisomers, such as in non-limiting examples where the term pyrrolyl may also include 2H-pyrrolyl, 3H-pyrrolyl and the like, the term pyrazolyl may also include 1H-pyrazolyl and the like, the term imidazolyl may also include 1H-imidazolyl and the like, the term triazolyl may also include 1H-1,2,3-triazolyl and the like, the term oxadiazolyl may also include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and the like, the term tetrazolyl may also include 1H-tetrazolyl, 2H-tetrazolyl and the like, the term indolyl may also include 1H-indolyl and the like, the term indazolyl may also include 1H-indazolyl and the like, the term indazolyl may also include 1H-in
  • heterocyclyl generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, but not limited to, oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, triazolidinyl,
  • 1,4-benzodioxanyl 2,3-dihydro-1,4-benzodioxinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl,
  • a heterocyclyl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.
  • heterocyclyl radical may differ, such as in non- limiting examples where 1,3-benzodioxolyl may also be referred to as benzo[d][1,3]dioxolyl and 2,3-dihydro-1,4-benzodioxinyl may also be referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl.
  • C1-6alkoxy-C1-6alkyl refers to a radical of the
  • C 1-6 alkoxy-carbonyl refers to a radical of the
  • C1-6alkoxy-carbonyl-C1-6alkyl refers to a radical of the formula: -C 1-6 alkyl-C(O)-O-C 1-6 alkyl.
  • C1-6alkoxy-carbonyl-amino refers to a radical of the formula: -NH-C(O)-O-C1-6alkyl.
  • C 1-6 alkyl-amino refers to a radical of the
  • C 1-6 alkyl-carbonyl refers to a radical of the
  • C1-6alkyl-carbonyl-amino refers to a radical of the
  • amino-carbonyl refers to a radical of the formula: -C(O)-NH 2 .
  • aryl-C1-6alkoxy refers to a radical of the
  • aryl-oxy refers to a radical of the formula: -O-aryl.
  • aryl-C 1-6 alkyl refers to a radical of the formula: -C 1-6 alkyl-aryl.
  • benzoxy-carbonyl refers to a radical of the
  • halo or“halogen” generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo.
  • halo-C1-6alkoxy refers to a radical of the
  • halo-C1-6alkyl refers to a radical of the
  • carboxyl refers to a radical of the formula: -COOH, -C(O)OH or -CO2H.
  • C 1-6 alkyl-carboxyl refers to a radical of the formula: -C 1-6 alkyl- COOH, -C1-6alkyl-C(O)OH or -C1-6alkyl-CO2H.
  • hydroxy refers to a radical of the formula: -OH.
  • hydroxy-C 1-6 alkoxy-C 1-6 alkyl refers to a radical of the formula: -C1-6alkyl-O-C1-6alkyl-OH.
  • hydroxy-C1-6alkyl refers to a radical of the
  • substituted means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom’s normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown.
  • one or more substituents having a double bond may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I) or Formula (II).
  • a double bond is intended for those substituents.
  • the term“and the like,” with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound.
  • each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.
  • the terms“independently selected,” or“each selected” refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I) or Formula (II), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence.
  • a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein.
  • each instance of” or“in each instance, when present,” when used preceding a phrase such as“...C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C1-4alkyl, heterocyclyl and heterocyclyl-C1-4alkyl,” are intended to refer to the C3-10cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent.
  • the term“form” means a compound of Formula (I) or Formula (II) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • the form of the compound of Formula (I) or Formula (II) is a free acid, free base or salt thereof.
  • the form of the compound of Formula (I) or Formula (II) is a salt thereof.
  • the form of the compound of Formula (I) or Formula (II) is an isotopologue thereof.
  • the form of the compound of Formula (I) or Formula (II) is a stereoisomer, racemate, enantiomer or diastereomer thereof.
  • the form of the compound of Formula (I) or Formula (II) is a tautomer thereof.
  • the form of the compound of Formula (I) or Formula (II) is a pharmaceutically acceptable form.
  • the compound of Formula (I) or Formula (II) or a form thereof is isolated for use.
  • the term“isolated” means the physical state of a compound of Formula (I) or Formula (II) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be
  • the term“protected” means that a functional group in a compound of Formula (I) or Formula (II) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction.
  • Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T.W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
  • Such functional groups include hydroxy, phenol, amino and carboxylic acid.
  • Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl),

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PCT/US2019/038895 2018-06-27 2019-06-25 Heteroaryl compounds for treating huntington's disease Ceased WO2020005877A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EA202092899A EA202092899A1 (ru) 2018-06-27 2019-06-25 Гетероарильные соединения для лечения болезни гентингтона
AU2019294482A AU2019294482B2 (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating Huntington's disease
MX2020014315A MX2020014315A (es) 2018-06-27 2019-06-25 Compuestos de heteroarilo para tratar la enfermedad de huntington.
US17/254,828 US12139499B2 (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating Huntington's disease
JP2020572894A JP7515415B2 (ja) 2018-06-27 2019-06-25 ハンチントン病を処置するためのヘテロアリール化合物
CN201980050967.1A CN112805280B (zh) 2018-06-27 2019-06-25 用于治疗亨廷顿氏病的杂芳基化合物
NZ771342A NZ771342B2 (en) 2019-06-25 Heteroaryl compounds for treating huntington's disease
BR112020026534-9A BR112020026534A2 (pt) 2018-06-27 2019-06-25 Compostos de heteroarila para o tratamento da doença de huntington
KR1020207036998A KR20210038845A (ko) 2018-06-27 2019-06-25 헌팅턴병 치료를 위한 헤테로아릴 화합물
EP19736947.3A EP3814345B8 (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating huntington's disease
SG11202012869SA SG11202012869SA (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating huntington's disease
CA3104516A CA3104516A1 (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating huntington's disease
IL279714A IL279714A (en) 2018-06-27 2020-12-23 Heteroaryl compounds for the treatment of Huntington's disease
AU2022209304A AU2022209304A1 (en) 2018-06-27 2022-07-28 Heteroaryl compounds for treating Huntington's disease
JP2024072881A JP2024105367A (ja) 2018-06-27 2024-04-26 ハンチントン病を処置するためのヘテロアリール化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690540P 2018-06-27 2018-06-27
US62/690,540 2018-06-27

Publications (1)

Publication Number Publication Date
WO2020005877A1 true WO2020005877A1 (en) 2020-01-02

Family

ID=67185796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/038895 Ceased WO2020005877A1 (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating huntington's disease

Country Status (13)

Country Link
US (1) US12139499B2 (enExample)
EP (1) EP3814345B8 (enExample)
JP (2) JP7515415B2 (enExample)
KR (1) KR20210038845A (enExample)
CN (1) CN112805280B (enExample)
AU (2) AU2019294482B2 (enExample)
BR (1) BR112020026534A2 (enExample)
CA (1) CA3104516A1 (enExample)
EA (1) EA202092899A1 (enExample)
IL (1) IL279714A (enExample)
MX (1) MX2020014315A (enExample)
SG (1) SG11202012869SA (enExample)
WO (1) WO2020005877A1 (enExample)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
US11008572B2 (en) 2017-08-04 2021-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2022194801A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiazolopyrimidinone derivatives
WO2022194802A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiadiazolopyrimidone derivatives
WO2022194800A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thienopyrimidinone derivatives
WO2022208170A1 (en) 2021-03-29 2022-10-06 Novartis Ag The use of the splicing modulator brataplam for slowing progression of huntington's disease
US11638706B2 (en) 2015-12-10 2023-05-02 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11780839B2 (en) 2018-03-27 2023-10-10 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11806346B2 (en) 2020-05-13 2023-11-07 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2023225244A1 (en) * 2022-05-20 2023-11-23 Biogen Ma Inc. Heterocyclic compounds for treating huntington's disease
US11845744B2 (en) 2019-02-05 2023-12-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
US11964971B2 (en) 2019-02-06 2024-04-23 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP4142717A4 (en) * 2020-04-28 2024-05-29 Kymera Therapeutics, Inc. IRAQ INHIBITORS AND THEIR USES
WO2024218207A1 (en) * 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives
US12139499B2 (en) 2018-06-27 2024-11-12 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2025111408A1 (en) * 2023-11-21 2025-05-30 Biogen Ma Inc. Compounds for treating spinal muscular atrophy and huntington's disease
US12509460B2 (en) 2019-02-05 2025-12-30 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US12522597B2 (en) 2019-02-06 2026-01-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US12577226B2 (en) 2019-05-13 2026-03-17 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116262758B (zh) * 2021-12-15 2025-02-28 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
KR20240152239A (ko) * 2023-04-11 2024-10-21 보로노이 주식회사 피라졸로피리딘 유도체 화합물 및 이의 용도

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163464A1 (en) * 2007-12-20 2009-06-25 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009114874A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009126635A1 (en) * 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
WO2010071819A1 (en) * 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
EP2560008A2 (en) * 2011-08-18 2013-02-20 Korea Institute of Science and Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
WO2017100726A1 (en) * 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
WO2017175068A1 (en) * 2016-04-08 2017-10-12 Mankind Pharma Ltd. Thiazolopyridine derivatives as gpr119 agonists

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (enExample) 1963-04-04 1900-01-01
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5599816A (en) 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
EP0640083A1 (en) 1992-05-13 1995-03-01 E.I. Du Pont De Nemours And Company Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides
DE69435005T2 (de) 1993-05-11 2008-04-17 The University Of North Carolina At Chapel Hill Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
WO1996039407A1 (en) 1995-06-06 1996-12-12 Abbott Laboratories Quinolizinone type compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
CA2269561C (en) 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
HK1040076A1 (zh) 1998-09-21 2002-05-24 希雷生物化学有限公司 作为整联蛋白抑制剂的喹嗪酮
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
EP1652839A3 (en) 1999-10-28 2006-07-05 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
WO2002038738A2 (en) 2000-11-09 2002-05-16 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
WO2002087589A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Medicine for inhibiting drug elimination pump
JP2005516005A (ja) 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Ｇｓｋ−３阻害剤として有用なピリミジンベースの化合物
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
CA2493458A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US7423133B2 (en) 2002-08-23 2008-09-09 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
DE60326894D1 (de) 2002-09-30 2009-05-07 Neurosearch As 1,4-Diazabicycloalkanderivate, deren Herstellung und Verwendung
WO2004043458A1 (en) 2002-11-12 2004-05-27 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US20070078144A1 (en) 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
US20040224952A1 (en) 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
WO2004113335A2 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
GB0315494D0 (en) 2003-07-02 2003-08-06 Biofocus Plc Compounds which bind to the active site of protein kinase enzymes
BRPI0413234A (pt) 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
KR20060127909A (ko) 2003-12-24 2006-12-13 비오타 사이언티픽 매니지먼트 피티와이 엘티디 호흡기 다핵체 바이러스 감염 치료용 다환 물질
SE0400184D0 (sv) 2004-01-30 2004-01-30 Fyrkloevern Scandinavia Ab New therapeutical use
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
ZA200609267B (en) 2004-04-08 2009-02-25 Targegen Inc Benzotriazine inhibitors of kinases
EP1732560A4 (en) 2004-04-08 2010-08-18 Neurogen Corp SUBSTITUTED CINNOLINE-4-YLAMINE
BRPI0510560A (pt) 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2006219453A (ja) 2005-02-14 2006-08-24 Tokyo Univ Of Pharmacy & Life Science キノリン環を母核とする金属識別型二波長性蛍光分子
US7563601B1 (en) 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US7576110B2 (en) 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
WO2007056580A2 (en) 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
US20070105807A1 (en) 2005-11-10 2007-05-10 Sazani Peter L Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease
RU2008110911A (ru) 2005-12-06 2010-01-20 Ньюросерч А/С (DK) Новые диазабициклические арильные производные и их медицинское применение
WO2007071055A1 (en) 2005-12-21 2007-06-28 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP5425474B2 (ja) 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ， インコーポレーテッド ハンチンチン対する、組成物及びその使用
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
CN101410385B (zh) 2006-03-28 2011-08-24 高点制药有限责任公司 具有组胺h3受体活性的苯并噻唑类
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007133756A2 (en) 2006-05-15 2007-11-22 Neurogen Corporation Crf1 receptor ligands comprising heteroaryl fused bicycles
WO2007135121A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2008014822A1 (en) 2006-08-03 2008-02-07 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US20100029685A1 (en) 2006-10-25 2010-02-04 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
DE602007012308D1 (de) 2006-12-22 2011-03-10 Avexa Ltd Bicyclische pyrimidinone und deren verwendung
US20080171792A1 (en) 2006-12-28 2008-07-17 Jobdevairakkam Christopher New Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders
FR2914188B1 (fr) 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
SI2193133T1 (sl) 2007-09-27 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
US20100267712A1 (en) 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009131958A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
CA2728376C (en) 2008-06-20 2015-05-12 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives/mao inhibitors for treating depression
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
US8318732B2 (en) 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
WO2010019243A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Methods for treating viral infections
WO2010024903A1 (en) 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
US20110224187A1 (en) 2008-10-16 2011-09-15 Anandan Palani Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
WO2010145208A1 (en) 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
NZ599032A (en) 2009-09-11 2014-09-26 Isis Pharmaceuticals Inc Modulation of huntingtin expression
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
US8754220B2 (en) 2009-11-20 2014-06-17 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide M1 receptor positive allosteric modulators
CN102812023A (zh) 2010-01-13 2012-12-05 韩国巴斯德研究所 抗感染吡啶并(1,2-a)嘧啶类
WO2011097644A2 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
WO2011097641A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
EP3561060A1 (en) 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
US20130225659A1 (en) 2010-07-19 2013-08-29 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
CN102617548A (zh) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
EA034451B1 (ru) 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US9447075B2 (en) 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
EP2742056B2 (en) 2011-08-11 2020-06-10 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
EP2751269B1 (en) 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
WO2013059606A1 (en) 2011-10-21 2013-04-25 Tufts Medical Center, Inc. Compounds and methods for the treatment of muscular disease, and related screening methods
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
ES2606630T3 (es) 2011-11-28 2017-03-24 Novartis Ag Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2733644T3 (es) 2012-01-26 2019-12-02 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2013151877A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2014012050A2 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP4144845B1 (en) 2012-10-12 2024-04-24 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
CA2887884A1 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
PL2911671T3 (pl) 2012-10-25 2018-11-30 Usher Iii Initiative, Inc. Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera
JP6255711B2 (ja) 2012-11-01 2018-01-10 株式会社リコー エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014121287A2 (en) 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
CN105026398B (zh) 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
WO2014184163A1 (en) 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
RU2673542C2 (ru) 2013-06-25 2018-11-28 Ф. Хоффманн-Ля Рош Аг Соединения для лечения спинальной мышечной атрофии
EA030631B1 (ru) 2013-07-31 2018-09-28 Новартис Аг 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
CN105392790B (zh) 2013-08-19 2019-04-19 豪夫迈·罗氏有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
WO2015095446A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
WO2015136947A1 (en) 2014-03-14 2015-09-17 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
AU2015231239B2 (en) 2014-03-19 2018-11-29 Amydis, Inc. Amyloid targeting agents and methods of using the same
DK3143025T3 (da) 2014-05-15 2019-12-09 Hoffmann La Roche Forbindelser til behandling af spinal muskelatrofi
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3157875A2 (en) 2014-06-17 2017-04-26 Novozymes A/S Biological phosphorus removal from wastewater
CA2952895C (en) 2014-06-25 2023-09-26 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
JP6672296B2 (ja) 2014-10-31 2020-03-25 ザ ジェネラル ホスピタル コーポレイション 強力なγ−セクレターゼモジュレータ
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US20180282347A1 (en) 2014-12-02 2018-10-04 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pest control agents
SMT201900347T1 (it) 2014-12-24 2019-07-11 Uniqure Ip Bv Soppressione del gene huntingtina indotta da rnai
PL3244891T3 (pl) 2015-01-16 2022-12-27 The General Hospital Corporation Związki poprawiające splicing mRNA
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
GB201502567D0 (en) 2015-02-16 2015-04-01 Sentinel Oncology Ltd Pharmaceutical compounds
CN112679467B (zh) * 2015-03-11 2024-11-01 Fmc公司 杂环取代的二环唑杀有害生物剂
GB201506933D0 (en) 2015-04-23 2015-06-10 Sentinel Oncology Ltd Pharmaceutical compounds
JP6749343B2 (ja) 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN108025089A (zh) 2015-07-22 2018-05-11 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP6659841B2 (ja) 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物
JP2018533594A (ja) 2015-11-12 2018-11-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 筋萎縮性側索硬化症を処置するための化合物
US10383867B2 (en) 2015-11-28 2019-08-20 Russell Dahl Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
EP4001277A3 (en) 2016-03-11 2022-09-14 AC Immune SA Bicyclic compounds for diagnosis and therapy
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN109477108A (zh) 2016-05-04 2019-03-15 波涛生命科学有限公司 寡核苷酸组合物和其方法
AU2017274199B2 (en) 2016-05-31 2021-09-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US10730868B2 (en) 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
US11857599B2 (en) 2017-04-03 2024-01-02 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
EP3755699A1 (en) 2018-02-21 2020-12-30 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
BR112020019385A2 (pt) 2018-03-21 2021-03-30 Relay Therapeutics, Inc. Inibidores de shp2 fosfatase e métodos de uso dos mesmos
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
EP3937942A4 (en) 2019-03-15 2022-11-16 Skyhawk Therapeutics, Inc. COMPOSITIONS AND METHODS FOR CORRECTING ABERRANT SPLICING
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
US20240216369A1 (en) 2019-11-01 2024-07-04 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
WO2021207453A1 (en) 2020-04-09 2021-10-14 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
AU2021380758A1 (en) 2020-11-12 2023-06-15 Ptc Therapeutics Inc. Novel rna transcript
CA3227287A1 (en) 2021-07-30 2023-02-02 Suresh Babu Heteroaryl compounds for treating huntington's disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163464A1 (en) * 2007-12-20 2009-06-25 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009114874A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009126635A1 (en) * 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
WO2010071819A1 (en) * 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
EP2560008A2 (en) * 2011-08-18 2013-02-20 Korea Institute of Science and Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
WO2017100726A1 (en) * 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
WO2017175068A1 (en) * 2016-04-08 2017-10-12 Mankind Pharma Ltd. Thiazolopyridine derivatives as gpr119 agonists

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"The Orange Book", FOOD & DRUG ADMINISTRATION
ANDERSON ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS
P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, vol. 33, 1986, pages 201 - 217
P. STAHL ET AL.: "Handbook of Pharmaceutical Salts. Properties, Selection and Use.", 2002, WILEY-VCH
S. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 - 19
T. HIGUCHIW. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
T.W. GREENE ET AL.: "Protective Groups in organic Synthesis", 1991, WILEY

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11638706B2 (en) 2015-12-10 2023-05-02 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US12384789B2 (en) 2017-06-05 2025-08-12 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11008572B2 (en) 2017-08-04 2021-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11603531B1 (en) 2017-08-04 2023-03-14 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11326165B1 (en) 2017-08-04 2022-05-10 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11021708B2 (en) 2017-08-04 2021-06-01 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11162101B2 (en) 2017-08-04 2021-11-02 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11091475B2 (en) 2017-08-04 2021-08-17 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11434489B1 (en) 2017-08-04 2022-09-06 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11780839B2 (en) 2018-03-27 2023-10-10 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US12139499B2 (en) 2018-06-27 2024-11-12 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11845744B2 (en) 2019-02-05 2023-12-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US12509460B2 (en) 2019-02-05 2025-12-30 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11964971B2 (en) 2019-02-06 2024-04-23 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US12522597B2 (en) 2019-02-06 2026-01-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US12577226B2 (en) 2019-05-13 2026-03-17 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
EP4142717A4 (en) * 2020-04-28 2024-05-29 Kymera Therapeutics, Inc. IRAQ INHIBITORS AND THEIR USES
US11806346B2 (en) 2020-05-13 2023-11-07 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
JP2023532332A (ja) * 2020-07-02 2023-07-27 リミックス セラピューティクス インコーポレイテッド 核酸のスプライシング及び増殖性疾患の処置のためのモジュレーターとしての２－（インダゾール－５－イル）－６－（ピペリジン－４－イル）－１，７－ナフチリジン誘導体及び関連する化合物
JP2023532331A (ja) * 2020-07-02 2023-07-27 リミックス セラピューティクス インコーポレイテッド 核酸をスプライシングするため及び増殖性疾患を処置するための修飾因子としての５－［５－（ピペリジン－４－イル）チエノ［３，２－ｃ］ピラゾール－２－イル］インダゾール誘導体及び関連する化合物並びにスプライシングを調節するための化合物及び方法
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022194802A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiadiazolopyrimidone derivatives
WO2022194801A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiazolopyrimidinone derivatives
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
WO2022194800A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thienopyrimidinone derivatives
WO2022208170A1 (en) 2021-03-29 2022-10-06 Novartis Ag The use of the splicing modulator brataplam for slowing progression of huntington's disease
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2023225244A1 (en) * 2022-05-20 2023-11-23 Biogen Ma Inc. Heterocyclic compounds for treating huntington's disease
WO2024218207A1 (en) * 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives
WO2025111408A1 (en) * 2023-11-21 2025-05-30 Biogen Ma Inc. Compounds for treating spinal muscular atrophy and huntington's disease

Also Published As

Publication number Publication date
EA202092899A1 (ru) 2021-05-14
CA3104516A1 (en) 2020-01-02
AU2019294482B2 (en) 2022-09-01
US12139499B2 (en) 2024-11-12
AU2022209304A1 (en) 2022-08-25
JP7515415B2 (ja) 2024-07-12
BR112020026534A2 (pt) 2021-03-23
EP3814345A1 (en) 2021-05-05
IL279714A (en) 2021-03-01
EP3814345B8 (en) 2024-10-30
MX2020014315A (es) 2021-05-27
CN112805280A (zh) 2021-05-14
SG11202012869SA (en) 2021-01-28
JP2021528466A (ja) 2021-10-21
AU2019294482A1 (en) 2021-01-21
US20210284660A1 (en) 2021-09-16
NZ771342A (en) 2025-06-27
JP2024105367A (ja) 2024-08-06
EP3814345B1 (en) 2024-09-25
KR20210038845A (ko) 2021-04-08
CN112805280B (zh) 2024-12-06

Similar Documents

Publication Publication Date Title
JP7515415B2 (ja) ハンチントン病を処置するためのヘテロアリール化合物
US12384789B2 (en) Compounds for treating Huntington's disease
US12103926B2 (en) Compounds for treating huntington's disease
EP3814360B1 (en) Heteroaryl compounds for treating huntington's disease
WO2020005873A1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40043147B (en) Heteroaryl compounds for treating huntington's disease
HK40043147A (en) Heteroaryl compounds for treating huntington's disease
EA045014B1 (ru) Гетероарильные соединения для лечения болезни гентингтона
EA043655B1 (ru) Соединения для лечения болезни хантингтона
EA041957B1 (ru) Соединения для лечения болезни гентингтона
NZ796418A (en) Compounds for treating huntington's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19736947

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3104516

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020572894

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020026534

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019294482

Country of ref document: AU

Date of ref document: 20190625

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019736947

Country of ref document: EP

Effective date: 20210127

ENP Entry into the national phase

Ref document number: 112020026534

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201223

WWR Wipo information: refused in national office

Ref document number: 1020207036998

Country of ref document: KR

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020207036998

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 771342

Country of ref document: NZ